Fabien Praz – författare

Tricuspid Valve Regurgitation is a common valvular pathology, estimated to affect 1.6 million people in the USA alone. Even though guidelines recommend either medical therapy or surgical treatment, the misconception of the disorder as a benign disease - along with the high mortality rates of surgical intervention - has led to undertreatment of this disease and description of it as a “forgotten” valve. This text from international experts looks at the disease and the developing transcatheter interventions with promising potential for use in the clinical setting.